You are here

  • Home
  • Archive
  • Volume 4, Issue 1
  • Osteopontin is associated with disease severity and antiphospholipid syndrome in well characterised Swedish cases of SLE

Article info

Article menu

Download PDFPDF

Biomarker studies
Original research article
Osteopontin is associated with disease severity and antiphospholipid syndrome in well characterised Swedish cases of SLE

Authors

  • Lina Wirestam Rheumatology/Division of Neuro and Inflammation Sciences, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden PubMed articlesGoogle scholar articles
  • Martina Frodlund Rheumatology/Division of Neuro and Inflammation Sciences, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden PubMed articlesGoogle scholar articles
  • Helena Enocsson Rheumatology/Division of Neuro and Inflammation Sciences, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden PubMed articlesGoogle scholar articles
  • Thomas Skogh Rheumatology/Division of Neuro and Inflammation Sciences, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden PubMed articlesGoogle scholar articles
  • Jonas Wetterö Rheumatology/Division of Neuro and Inflammation Sciences, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden PubMed articlesGoogle scholar articles
  • Christopher Sjöwall Rheumatology/Division of Neuro and Inflammation Sciences, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Lina Wirestam; lina.wirestam{at}liu.se
View Full Text

Citation

Wirestam L, Frodlund M, Enocsson H, et al
Osteopontin is associated with disease severity and antiphospholipid syndrome in well characterised Swedish cases of SLE
Lupus Science & Medicine 2017;4:e000225. doi: 10.1136/lupus-2017-000225

Publication history

  • Received April 10, 2017
  • Revision received May 19, 2017
  • Accepted May 28, 2017
  • First published July 28, 2017.
Online issue publication 
April 30, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/